抗妇炎胶囊治疗盆腔炎性疾病后遗症-慢性盆腔痛药物经济学评价  

Economic evaluation of Kangfuyan capsules in the treatment of sequelae of pelvic inflammatory diseaseschronic pelvic pain

作　　者：刘朝晖 赵红[2] 路遥[3] 李勤[4] 夏敏[5] 邹婷 金哲[3] LIU Zhaohui;ZHAO Hong;LU Yao;LI Qin;XIA Min;ZOU Ting;JIN Zhe(Department of Gynecology,Beijing Obstetrics and Gynecology Hospital,Capital Medical University,Beijing Maternal and Child Health Care Hospital,Beijing 100026;China-Japan Friendship Hosipital,Beijing 100029;Department of Gynecology,Dongfang Hospital Affiliated to Beijing University of Chinese Medicine,Beijing 100078;The Second Affiliated Hospital of Shaanxi College of Traditional Chinese Medicine,Xianyang,Shaanxi Province 712000;Chongqing Hospital of Traditional Chinese Medicine,Chongqing 400021;Women's Reproductive Health Drug Research Professional Committee of China Association of Traditional Chinese Medicine,Beijing 100024,China)

机构地区：[1]首都医科大学附属北京妇产医院/北京妇幼保健院妇科,北京100026 [2]中日友好医院,北京100029 [3]北京中医药大学东方医院妇科,北京100078 [4]陕西中医学院第二附属医院,陕西咸阳712000 [5]重庆市中医院,重庆400021 [6]中国中药协会女性生殖健康药物研究专业委员会,北京100024

出　　处：《中国妇产科临床杂志》2024年第4期345-348,共4页Chinese Journal of Clinical Obstetrics and Gynecology

基　　金：国家中医药管理局(SATCM-2015-BZ402)。

摘　　要：目的通过成本-效果和成本-效用分析,比较抗妇炎胶囊与宫炎平胶囊治疗盆腔炎性疾病后遗症(SPID)-慢性盆腔痛(CPP)的经济学优劣。方法2014年9月至2015年11月,采用随机、双盲、阳性药平行对照设计,筛选10家研究中心262例受试者,最终240例SPID-CPP患者按照1:1比例随机分配到抗妇炎胶囊组(研究组)和宫炎平胶囊组(对照组)。2023年1月至2023年12月,对两组患者进行电话随访。以下腹痛视觉模拟评分法(VAS)评分、中医证候愈显率、疾病愈显率、盆腔痛复发率和盆腔炎性疾病发生率作为效果指标,以质量调整生命年(QALYs)为效用指标,治疗3个月经周期后进行成本-效果和成本-效用分析。结果研究组人均总成本981.96元,略高于对照组的860.64元(P<0.05)。与对照组相比,研究组受试者下腹痛人均每多降低1分,需多花费131.87元;疾病治愈和显效率每增加1个百分点,需多花费6.33元;中医证候治愈和显效率每增加1个百分点,需多花费8.42元;CPP复发率每减少1个百分点,人均需多花费5.37元。与对照组相比,研究组人均每多获得1个QALY需多花费12132元。结论在SPID-CPP患者的治疗中,抗妇炎胶囊显示出良好的安全性和有效性,与宫炎平胶囊相比,具有一定的经济学优势。Objective To compare the economic advantages and disadvantages of Kangfuyan Capsules and Gongyanping Capsules in the treatment of pelvic inflammatory disease sequelae(SPID)-chronic pelvic pain(CPP)through cost-effectiveness and cost-effectiveness analysis.Methods From September 2014 to November 2015,262 subjects from 10 research centers were selected by a randomized,double-blind,positive-drug parallel control design.Finally,240 SPID-CPP patients were randomly assigned to the anti gynecological inflammation capsule group(study group)and the Gongyanping capsule group(control group)in a 1:1 ratio.Patients in both groups were followed up by telephone from January 2023 to December 2023.The following visual analogue scale(VAS)for abdominal pain,the recovery rate of traditional Chinese medicine syndromes,the recovery rate of diseases,the recurrence rate of pelvic pain,and the incidence rate of pelvic inflammatory diseases are used as effectiveness indicators.Quality adjusted life years(QALYs)were used as efficacy indicators,and cost-effectiveness and cost-effectiveness analyses were conducted after three menstrual cycles of treatment.Results The total cost per capita in the research group was 981.96 yuan,slightly higher than the control group's 860.64 yuan(P<0.05).Compared with the control group,the lower abdominal pain per person in the study group decreased by 1 point,which more cost 131.87 yuan.Increase of 1 percentage point in disease recovery rate,an additional cost of 6.33 yuan is required;For every 1 percentage point increase in the recovery rate of traditional Chinese medicine syndromes,an additional cost of 8.42 yuan is required;For every 1 percentage point decrease in CPP recurrence rate,an additional cost of 5.37 yuan per person is required.Compared with the control group,the study group spent an additional 12132 yuan per person for every additional QALY obtained.Conclusions In the treatment of SPID-CPP patients,Kangfuyan Capsules shows good safety and efficacy,and has certain economic advantages compared wit

关 键 词：抗妇炎胶囊 慢性盆腔痛 盆腔炎性疾病后遗症 成本-效果分析 成本-效用分析 药物经济学评价 

分 类 号：R271.9[医药卫生—中西医结合]